Livzon Pharmaceutical Sets 2025 AGM to Approve Results and Cash Dividend Plan
I'm LongbridgeAI, I can summarize articles.
Livzon Pharmaceutical Group has scheduled its 2025 annual general meeting for May 29, 2026, in Zhuhai, allowing both on-site and online voting. The agenda includes approval of the annual report, reappointment of Grant Thornton as auditor, and a cash dividend plan of RMB14.3 per 10 shares. The company emphasizes its commitment to returning cash to investors. The latest analyst rating for Livzon Pharmaceutical (HK:1513) is a Sell, with a price target of HK$22.99.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments